The early-stage biotech company, focused on developing therapies for rare diseases, has announced an asset purchase agreement with Codexis, Inc. for the acquisition of Codexis' investigational engineered enzymes that target Fabry and Pompe diseases.
CAMBRIDGE, Mass., July 10, 2024 /PRNewswire-PRWeb/ -- Crosswalk Therapeutics (Crosswalk), a seed-stage biotech company focused on developing therapies for rare diseases, has announced an asset purchase agreement with Codexis, Inc. (NASDAQ: CDXS) for the acquisition of Codexis' investigational engineered enzymes that target Fabry and Pompe diseases. These assets will integrate into Crosswalk's rapidly advancing R&D programs aimed at developing best-in-class enzyme replacement therapies.
"Patients with lysosomal storage diseases often face burdensome and frequent enzyme replacement infusions as part of current therapeutic options. While these treatments save lives, they often leave residual disease burden in tissues they don't reach, leading to poor prognoses over time," says Rizwana Islam, SVP and Head of Metabolism at Crosswalk.
Crosswalk's novel protein biodistribution platform offers a plug-and-play solution for delivering engineered enzymes into hard-to-reach tissues. The combination of these technologies into a single construct potentially enables true best-in-class enzyme replacement and marks the first milestone in Crosswalk's relentless pursuit of functional cures. Convenient subcutaneous administration will reduce the burden of therapy for patients, caregivers, and families. Beyond initial efforts in Fabry and Pompe disease, the Crosswalk platform has the capability to improve and expand treatment options across a range of lysosomal storage diseases including those with neurological manifestations such as Metachromatic Leukodystrophy.
"Our Fabry and Pompe programs serve as the cornerstone of our efforts in the lysosomal storage disease space – and they're just the beginning of what we aim to achieve for the broader rare disease community." says Madhu Natarajan, CEO of Crosswalk Therapeutics.
About Crosswalk Therapeutics
Crosswalk Therapeutics (Crosswalk) is a seed stage biotech company whose mission is to relentlessly pursue functional cures for rare disease patients and their families. Crosswalk is initially focused on rare diseases, with future plans to expand its scope to include genetically defined common diseases. For more information, visit: https://www.linkedin.com/company/crosswalktx/.
Media Contact
Alan Clark, Crosswalk Therapeutics, 1 857-600-0231, [email protected], https://www.linkedin.com/company/crosswalktx/
SOURCE Crosswalk Therapeutics
Share this article